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Recently, HOXB13 has been established as a prostate
cancer susceptibility gene in North America, with a rela-
tive risk associated with a single missense mutation of
about 20. Ewing et al., sequenced over 200 genes in a pros-
tate cancer linkage region at 17q21-22 among 94 probands
of prostate cancer families, and found a recurrent muta-
tion in the HOXB13 gene (G84E) in four families. The
mutation co-segregated with prostate cancer. The geogra-
phical and ethnic extent of this founder allele has not yet
been determined. We assayed for the presence of the
G84E mutation in 3515 prostate cancer patients and 2604
controls from Poland. The G84E mutation predisposes to
prostate cancer in Poland. We expect that the G84E foun-
der mutation might be present in other Slavic populations.
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